CME: Management strategies for complications of chronic kidney disease (CKD): anemia and hyperphosphatemia

Cost: Free

View Offer chevron_right


Chronic Kidney Disease (CKD) affects about 15% of the general population in the United States according to data from the CDC’s National Health and Nutrition Examination Survey and causes a number of complications with anemia and hyperphosphatemia common among them. Anemia occurs in about 15% of patients and arises from a result of decreased production of erythropoietin (EPO) which signals bone marrow to produce red blood cells, whereas hyperphosphatemia occurs in the later stages of CKD because the kidney is the primary method by which the body maintains phosphate. This retention of phosphate leads to the development of CKD-Mineral Bone Disorder (CKD-MBD), with the literature suggesting that hyperphosphatemia occurs in a large portion of patients on dialysis based on usage of phosphate binders (PBs).

By the end of the session the participant will be able to:

  • Describe common complications that patients with CKD experience
  • Describe management strategies for anemia and hypherphosphatemia of CKD and their impact
  • Determine appropriateness of therapies for anemia and hypherphosphatemia of CKD, given a patient case
  • Describe effective management strategies for monitoring anemia and hyperphosphatemia in patients with CKD, taking into account dialysis status

Target Audience:

The following healthcare professionals (HCPs): nephrologists and primary care physicians; physician assistants, nurse practitioners, and pharmacists who practice in nephrology; and any other HCPs with an interest in or who clinically encounter patients with CKD.

Stay up-to-date

Receive special offers, keep up with MOC requirements and stay informed of the latest offerings in free online CME in your specialty.